Biotime-Nasdaq's best kept secret? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotime-Nasdaq's best kept secret?

BTIM 0.0001000

0.0%

Dec 5 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: John L. who wrote (982)	6/2/1998 11:39:00 PM
From: Stephen How	of 1432

I missed this point: (from mesaone's posting of Crossen's report: siliconinvestor.com The WSJ article stated that hextend failed to show an advantage over hespan and that additional studies in an ad hoc fashion are being planned to accentuate advantages but this may be too little too late. in this small study, 41% of patients did not get transfused. therefore, the patients who received blood transfusions were an especially small group and yet, in this group , the hextend patients experienced one liter less blood loss than the hespan patients (p<.03 in this small group). much more interestingly, every variable related to blood loss went in the same direction in favor of hextend. this includes fewer red blood cells transfused, less fresh frozen plasma used, less platelets used and less calcium transfused. The p=.03 for blood loss between the transfusion patients of the Hextend&reg and hetastarch groups is statistically significant. (Extex on the Motley Fool board posted a miswording of this Crossen statement, and I argued that the 1 L EBL difference was not a valid conclusion. However, the direct Crossen wording says that the results are SS!) I'm pretty sure the p=.03 takes into account the small N. If this analysis is correct, I think that the p will decrease further for larger N! I'm suprised that Biotime did not issue a press release on this analysis of the data. If true, this analysis is extremely important news, and clearly shows Hextend&reg's superiority over hetastarch. I will change my mind if this is true. Steve btim.dyn.ml.org

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next